Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
Lu Tang, Yinqiang Zhang, Yu Hu, et al.
BioMed Research International (2021) Vol. 2021, pp. 1-8
Open Access | Times Cited: 51

Showing 26-50 of 51 citing articles:

Vaccine Boosting CAR-T Cell Therapy: Current and Future Strategies
Emmanuel Owusu Ansah, Andy Baah, Emmanuel Boateng Agyenim
Advances in Cell and Gene Therapy (2023) Vol. 2023, pp. 1-9
Open Access | Times Cited: 7
Degradation of IKAROS prevents epigenetic progression of T cell exhaustion in a novel antigen-specific assay
Tristan Tay, Gayathri Bommakanti, Elizabeth Jaensch, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy
Sunčica Kapor, Milica Radojković, Juan F. Santibáñez
Acta Histochemica (2024) Vol. 126, Iss. 5-7, pp. 152183-152183
Closed Access | Times Cited: 2
Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy
Bingjie Fu, Rui Liu, Gongzhizi Gao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy
Yuki Fujiwara, Toshiki Kato, Futoshi Hasegawa, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 2, pp. 207-207
Open Access | Times Cited: 11
Altered transcription factor targeting is associated with differential peripheral blood mononuclear cell proportions in sarcoidosis
Christian Ascoli, Cody Schott, Yue Huang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 11
Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy
Aditi Mulgaonkar, Durga Udayakumar, Yaxing Yang, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 6
Combination of 4-1BB and DAP10 promotes proliferation and persistence of NKG2D(bbz) CAR-T cells
Wei Cheng, Kangfu Xia, Yucheng Xie, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 10
Update on the current and future use of CAR‐T to treat multiple myeloma
Zhubin Gahvari, Matthew Brunner, Timothy M. Schmidt, et al.
European Journal Of Haematology (2023) Vol. 112, Iss. 4, pp. 493-503
Open Access | Times Cited: 5
Engineered CAR-T cells: An immunotherapeutic approach for cancer treatment and beyond
Purva Khodke, Bajarang Vasant Kumbhar
Advances in protein chemistry and structural biology (2024), pp. 157-198
Closed Access | Times Cited: 1
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy
Ava Aghakhani, Parmida Sadat Pezeshki, Nima Rezaei
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 7, pp. 721-740
Open Access | Times Cited: 1
BRD4 inhibitor reduces exhaustion and blocks terminal differentiation in CAR-T cells by modulating BATF and EGR1
Songnan Sui, Mengjun Zhong, Shuxin Zhong, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 1
Degradation of IKZF1 prevents epigenetic progression of T cell exhaustion in an antigen-specific assay
Tristan Tay, Gayathri Bommakanti, Elizabeth Jaensch, et al.
Cell Reports Medicine (2024), pp. 101804-101804
Open Access | Times Cited: 1
The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
Dristhi Ragoonanan, Irtiza Sheikh, Sumit Gupta, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2286-2286
Open Access | Times Cited: 5
Targeting cancer-associated glycans as a therapeutic strategy in leukemia
Ashraf Abdullah Saad
All Life (2022) Vol. 15, Iss. 1, pp. 378-433
Open Access | Times Cited: 4
Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy
Li Yang, Yang Liu, Keyan Yang, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Killer fatigue: Transition to NK-cell-like phenotype is a signature of CAR-T cell exhaustion
Mihe Hong, Yvonne Y. Chen
Cell (2021) Vol. 184, Iss. 25, pp. 6017-6019
Open Access | Times Cited: 5
Challenges for CAR-T cell therapy in multiple myeloma: overcoming the tumor microenvironment
Jian Cui, Gang An, Lugui Qiu
Hematology and Oncology Discovery (2023) Vol. 2, Iss. 1
Open Access | Times Cited: 1
Simulating the Evolution of Signaling Signatures During CART-Cell and Tumor Cell Interactions
Viren Shah, Justin Womack, Anthony E. Zamora, et al.
2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC) (2023), pp. 1-5
Closed Access | Times Cited: 1
Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities
Milica Vukotić, Sunčica Kapor, Felipe Simón, et al.
Heliyon (2024) Vol. 10, Iss. 3, pp. e25081-e25081
Open Access
Unlocking hope: talquetamab in multiple myeloma treatment: a bispecific breakthrough targeting CD3 and GPRC5D
Suhaina Amir, Fatima Laique, Muhammad Mazhar Azam
International Journal of Scientific Reports (2024) Vol. 10, Iss. 6, pp. 221-224
Open Access
Recent Advancement in Car-T-Cell Therapy
Vivek Pazhamalai, G. Manideepa, R. Mathumida
Advances in medical diagnosis, treatment, and care (AMDTC) book series (2024), pp. 237-264
Closed Access
Novel Therapies in BCMA-exposed Relapsed/Refractory Multiple Myeloma: The Anti-BCMA Therapy-refractory Patient
Emma Golden, Sara Ingram, Henning Schade, et al.
touchREVIEWS in Oncology & Haematology (2022) Vol. 18, Iss. 1, pp. 59-59
Open Access | Times Cited: 2
Simulating the Evolution of Signaling Signatures during CART-Cell - Tumor Cell Interactions.
Viren Shah, Justin Womack, Anthony E. Zamora, et al.
PubMed (2023)
Closed Access
Immunotherapies in Biliary Tract Cancers: The Current Landscape
Chao Yin, Ali Alqhatani, Aiwu Ruth He
(2022), pp. 1-28
Closed Access

Scroll to top